The Food and Drug Administration on Friday approved the first personalized cell therapy to treat patients with advanced multiple myeloma. It will be marketed under the brand name Abecma by its makers, Bristol Myers Squibb and Bluebird Bio.
Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell that helps fight infections. In people with multiple myeloma, malignant plasma cells accumulate in the bone marrow, where they crowd out healthy blood cells, causing tumors, kidney damage, bone destruction, and impaired immune function.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
https://ift.tt/3cnRDe6
Business
Bagikan Berita Ini
0 Response to "FDA approves first personalized cell therapy for multiple myeloma - STAT"
Post a Comment